Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing

publication date: Sep 15, 2022

Great Bay Bio, a Hong Kong CRO developing AI-based bioprocessing platforms, closed a $15 million Pre-Series B funding led by Tiger Jade Capital. Tiger Jade was seeded by China’s TigerMed, a clinical CRO with clients who may need GBB’s services. GBB will use the funds to advance its AI-based bioprocessing platforms, build production facilities and form a global commercial development team. Also participating in the funding were AEF Greater Bay Area Fund (managed by Gobi Partners GBA), Vectr Ventures and an unnamed MNC. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital